The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Open accessAbstract
BACKGROUND: Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo once daily. The primary end point was metastasis-free survival (defined as the time from randomization to radiographic progression or as the time to death without radiographic progression). RESULTS: A total of 1401 patients (median PSA doubling time, 3.7 months) underwent randomization. As of June 28, 2017, a total of 219 of 933 patients (23%) in the enzalutamide group had metastasis or had died, as compared with 228 of 468 (49%) in the placebo group. The median metastasis-free survival was 36.6 months in the enzalutamide group versus 14.7 months in the placebo group (hazard ratio for metastasis or death, 0.29; 95% confidence interval, 0.24 to 0.35; P<0.001). The time to the first use of a subsequent antineoplastic therapy was longer with enzalutamide treatment than with placebo (39.6 vs. 17.7 months; hazard ratio, 0.21; P<0.001; such therapy was used in 15% vs. 48% of patients) as was the time to PSA progression (37.2 vs. 3.9 months; hazard ratio, 0.07; P<0.001; progression occurred in 22% vs. 69% of patients). At the first interim analysis of overall survival, 103 patients (11%) receiving enzalutamide and 62 (13%) receiving placebo had died. Adverse events of grade 3 or higher occurred in 31% of the patients receiving enzalutamide, as compared with 23% of those receiving placebo. CONCLUSIONS: Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationNatural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., Wynne, C., Murray, R., Zinner, N. R., Schulman, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.529 · Cited by 496
Self-citationMetastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., Soule, H., Clarke, N. W., Collette, L., Dignam, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9987 · Cited by 433
Self-citationEnzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
Self-citationShore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Self-citationNelson, J. B., Love, W., Chin, J. L., Saad, F., Schulman, C. C., Sleep, D. J., Qian, J., Steinberg, J., Carducci, M., & for the Atrasentan Phase 3 Study Group (2008) · Cancer · doi:10.1002/cncr.23864 · Cited by 245
Self-citationSmith, M. R., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., Marx, G., Miller, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6716 · Cited by 241
Self-citationBicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., & Schwartz, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2928 · Cited by 227
Smith, M. R., Cook, R., Lee, K., & Nelson, J. B. (2011) · Cancer · doi:10.1002/cncr.25762 · Cited by 178
Prostate cancer: ESMO Consensus Conference Guidelines 2012
Horwich, A., Hugosson, J., de Reijke, T. M., Wiegel, T., Fizazi, K. S., Kataja, V. V., Parker, C. C., Joaquim Bellmunt, B., Berthold, D., Bill‐Axelson, A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds624 · Cited by 149
Self-citationSuzuki, H., Okihara, K., Miyake, H., Fujisawa, M., Miyoshi, S., Matsumoto, T., Fujii, M., Takihana, Y., Usui, T., Matsuda, T., et al. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.05.045 · Cited by 146
Salvage Therapy With Bicalutamide 150 mg in Nonmetastatic Castration-resistant Prostate Cancer
Lodde, M., Lacombe, L., & Fradet, Y. (2010) · Urology · doi:10.1016/j.urology.2009.12.057 · Cited by 47
Afshar, M., Evison, F., James, N. D., & Patel, P. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.003 · Cited by 40
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Self-citationLiquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Metadata
- Authors
- Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., Krivoshik, A., & Sternberg, C. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-06-28
- Volume
- 378
- Issue
- 26
- Pages
- 2465-2474
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2810806599
- Cited by
- 1,035
- References
- 17
- FWCI
- 98.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.